AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30744880
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (2000 IU/day) + Omega-3 LCPUFA (722 mg/day DHA)
Trial: 28097633
Drug: Individualized meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized meropenem therapy based on a population PK/PD model
Trial: 15175633
Drug: Sour milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sour milk fermented with Lactobacillus helveticus containing 2.4-2.7 mg of Ile-Pro-Pro and 2.4-2.7 mg of Val-Pro-Pro per 1.5 dl, taken daily.
Trial: 15175633
Drug: Placebo (regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (regular sour milk), taken daily.
Trial: 9719049
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (0.3 U/kg body wt per day)
Trial: 7654109
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (combined response rate)
Trial: 2655256
Drug: Metimazole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metimazole (2.5 g)
Trial: 334611
Drug: Butacote (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butacote (300 mg daily)
Trial: 334611
Drug: fenclofenac (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenclofenac (1200 mg daily)
Trial: 25916220
Drug: Lubiprostone 24
RxNorm normalized name: LUBIPROSTONE 24MCG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone 24 μg twice daily for 12 weeks
Trial: 21192244
Drug: Artesunate-Amodiaquine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate-Amodiaquine (both formulations)
Trial: 21609157
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT)‐based brief intervention and education program
Trial: 11726841
Drug: Endoscopic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic injection therapy (epinephrine and polidocanol)
Trial: 11726841
Drug: No endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No endoscopic therapy (control group)
Trial: 3309199
Drug: Intrathecal methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal methotrexate (MTX) 15 mg
Trial: 3309199
Drug: Intrathecal methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal methotrexate (MTX) 15 mg plus cytosine arabinoside (Ara-C) 50 mg/m2
Trial: 3309199
Drug: Drugs administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs administered via Ommaya reservoir
Trial: 3309199
Drug: Drugs administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs administered via lumbar puncture
Trial: 3309199
Drug: Concurrent radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent radiotherapy to the CNS
Trial: 3309199
Drug: No concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No concurrent radiotherapy to the CNS
Trial: 31545914
Drug: 1,25(OH)2D3 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25(OH)2D3 (100 nmol/L, 12 h)
Trial: 29345161
Drug: Caffeine supplementation
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine supplementation (6 mg/kg body weight, 60 min pretrial)
Trial: 18490931
Drug: Cod diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod diet (3 x 150 g week(‐1))
Trial: 18490931
Drug: Salmon diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon diet (3 x 150 g week(‐1))
Trial: 17502874
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (DHA/EPA capsules, no seafood)
Trial: 15986036
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (GEM) with continuous infusion 5-FU (CI 5-FU)
Trial: 12185157
Drug: Off condition
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Off condition (no treatment)
Trial: 12185157
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Deep brain stimulation, Levodopa, both)
Trial: 359110
Drug: Meperidine 75
RxNorm normalized name: MEPERIDINE 75MG/ML INJ CARPUJECT LL 1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 75 to 150 mg
Trial: 30907180
Drug: Nutritional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional treatment (Control Group)
Trial: 31161927
Drug: Shilajit supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shilajit supplementation (125 or 250 mg bid)
Trial: 31161927
Drug: Shilajit supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shilajit supplementation (250 mg bid)
Trial: 26081815
Drug: Cediranib (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib (an inhibitor of vascular endothelial growth factor receptors) combined with carboplatin-paclitaxel
Trial: 16132055
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g per day of water-soluble fiber from oat bran
Trial: 11762655
Drug: Anticonvulsant medication
RxNorm normalized name: ANTICONVULSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsant medication
Trial: 10960380
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of 1.5% (60‐mg dose) plain mepivacaine (Group 1)
Trial: 10960380
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of 2% (80‐mg dose) plain mepivacaine (Group 2)
Trial: 10960380
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of plain mepivacaine
Trial: 17434095
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH), nadroparin calcium 3800 anti-factor Xa IU/0.4 mL twice daily for 10 days, then aspirin 80-300 mg once daily for 6 months
Trial: 17434095
Drug: Aspirin 160
RxNorm normalized name: aspirin 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 160 mg daily for 10 days, then aspirin 80-300 mg once daily for 6 months
Trial: 15685040
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with DDP (80 mg/m2 intravenously day 1 only) and VP-16 (80 mg/m2 intravenously days 1-3) every 3 weeks for 5 cycles without tamoxifen.
Trial: 15685040
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with DDP and VP-16 plus high-dose tamoxifen (80 mg orally twice per day for 5 days each cycle starting 1 day before DDP).
Trial: 11854640
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol (200 microg initially, increased to 300 microg)
Trial: 7541064
Drug: Zidovudine and
RxNorm normalized name: zidovudine and lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine and didanosine combination therapy for 2 years
Trial: 2355814
Drug: Acetazolamide (ACZ)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (ACZ) 500 mg
Trial: 30590606
Drug: Post-operative therapy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative therapy with capecitabine and oxaliplatin
Trial: 20500533
Drug: High adherence
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High adherence to drug (> 80% of days covered)
Trial: 20500533
Drug: Low adherence
RxNorm normalized name: dressing,low adherence and wound contact materials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low adherence to drug (< 50% of days covered)
Trial: 12365468
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of metformin
Trial: 10585981
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg of Adderall received in the morning only
Trial: 10585981
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg of MPH received twice (7:30 AM and 11:30 AM) with 0.15 mg/kg received at 3:30 PM
Trial: 10585981
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg of MPH at 3:30 PM
Trial: 1846848
Drug: Cisplatin 3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 3.2 mg/m2/24 hr with 66 Gy in 33 fractions over 6 1/2 weeks for NSCLC
Trial: 1846848
Drug: Cisplatin 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 4.0 mg/m2/24 hr with 45 Gy in 25 fractions over 5 weeks for rectal carcinoma
Trial: 1846848
Drug: Cisplatin 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 5.0 mg/m2/24 hr
Trial: 1846848
Drug: Further external
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further external beam therapy up to 59.4 Gy
Trial: 1846848
Drug: Toxicity related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toxicity related to cisplatin dose
Trial: 1846848
Drug: Maximum tolerated
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum tolerated dose
Trial: 27040515
Drug: BNP tertile
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP tertile 1 (BNP ≤ 376 pg/mL)
Trial: 27040515
Drug: BNP tertile
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP tertile 2 (BNP 377 to 792 pg/mL)
Trial: 27040515
Drug: BNP tertile
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP tertile 3 (BNP ≥ 793 pg/mL)
Trial: 24339313
Drug: Oral hygienic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygienic care program (OHCP) including tooth brushing with an inter-dental brush and tongue cleaner, and cleaning with chlorhexidine, administered once per day for a mean duration of 2.2 weeks.
Trial: 21288666
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg DM Se
Trial: 21288666
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg DM Se
Trial: 21288666
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg DM Se
Trial: 21288666
Drug: 0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/kg DM Se (Control)
Trial: 17503747
Drug: Induction/maintenance (IM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction/maintenance (IM) therapy: two NRTIs + one NNRTI + one protease inhibitor for 24-32 weeks, followed by two NRTIs + NNRTI
Trial: 17503747
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (ST): two NRTIs + NNRTI
Trial: 17503747
Drug: Induction/maintenance (IM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction/maintenance (IM) therapy
Trial: 15201565
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg, flexible)
Trial: 9554347
Drug: Alprostadil-prazosin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprostadil-prazosin combination (500/2,000 microg)
Trial: 29344729
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) supplementation (0.3 g kg bm-1)
Trial: 29344729
Drug: Placebo (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sodium chloride, 0.21 g kg bm-1)
Trial: 27315514
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg DCS administered 1 hr prior to the final three sessions of CBT
Trial: 27315514
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered 1 hr prior to the final three sessions of CBT
Trial: 25661281
Drug: Tiotropium 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 5 μg once-daily
Trial: 25661281
Drug: Tiotropium 2.5
RxNorm normalized name: TIOTROPIUM 2.5MCG/ACTUAT 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 2.5 μg twice-daily
Trial: 25661281
Drug: Tiotropium (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (both dosing regimens)
Trial: 23161599
Drug: Buprenorphine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (mean dose: 14.00 mg)
Trial: 23161599
Drug: Methadone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (mean dose: 52.50 mg)
Trial: 23161599
Drug: Escalating voucher
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating voucher incentives for drug-free urine samples (MOTHER-trial only)
Trial: 23161599
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine solution for neonatal abstinence syndrome treatment
Trial: 21903536
Drug: Total-etch adhesive
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total-etch adhesive system with diamond bur preparation
Trial: 21903536
Drug: Total-etch adhesive
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total-etch adhesive system with Er:YAG laser preparation
Trial: 21903536
Drug: Self-etch adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etch adhesive system with diamond bur preparation
Trial: 21903536
Drug: Self-etch adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etch adhesive system with Er:YAG laser preparation
Trial: 18353012
Drug: Conventional bur
RxNorm normalized name: bur oak pollen extract
DrugBank: Quercus macrocarpa pollen (DB10738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional bur treatment
Trial: 16115991
Drug: morphine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine + ketamine (n = 8)
Trial: 16115991
Drug: morphine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine + placebo (n = 8)
Trial: 12693594
Drug: Antibiotic sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic sensitivity testing
Trial: 2137066
Drug: Sorbinil (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbinil (250 mg day-1)
Trial: 7011622
Drug: 3 g/24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/24 hr frusemide (sustained)
Trial: 7011622
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g frusemide (single injection)
Trial: 12955305
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oxycodone
Trial: 14729881
Drug: MBvO gymnastics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBvO gymnastics twice weekly (MBvO2; n = 68)
Trial: 14729881
Drug: MBvO gymnastics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBvO gymnastics once weekly (MBvO1; n = 125)
Trial: 11854673
Drug: Poor oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor oral hygiene before treatment
Trial: 7926910
Drug: 4-aminosalicylic acid
RxNorm normalized name: 4-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-aminosalicylic acid (4-ASA) 1.5 g/d, slow release tablets
Trial: 7926910
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (5-ASA) 1.5 g/d, slow release tablets
Trial: 3135011
Drug: Whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole cell pertussis vaccine (3 doses, one month apart)
Trial: 31305450
Drug: fentanyl-based intravenous
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl-based intravenous patient-controlled analgesia with low dose of ketamine (fk-IVPCA)
Trial: 24107877
Drug: noojerone (memantine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: noojerone (memantine) in addition to standard therapy for 6 months
Trial: 24107877
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy only
Trial: 19848371
Drug: Wavefront-guided optimized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wavefront-guided optimized path difference custom aspheric treatment (OPDCAT group)
Trial: 17006746
Drug: Tiotropium (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (18 mcg)
Trial: 3606915
Drug: i.v. lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. lignocaine 1.5 mg kg‐1 plus 2 mg kg‐1 h‐1
Trial: 23115322
Drug: High-dose beta-blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose beta-blockers
Trial: 11198725
Drug: Flurbiprofen 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 12.5 mg
Trial: 12011823
Drug: Flurbiprofen 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 5.0 mg
Trial: 12011823
Drug: Flurbiprofen 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 2.5 mg
Trial: 12011823
Drug: Flurbiprofen (per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (per mg increase)
Trial: 7914122
Drug: Proxodolol (Pd)
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxodolol (Pd) single dose of 0.04-0.08 g
Trial: 7914122
Drug: Propranolol (Pr)
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (Pr) single dose of 0.04-0.08 g
Trial: 7914122
Drug: Proxodolol (Pd)
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxodolol (Pd) course treatment mean daily dose of 186 +/- 24 mg
Trial: 7914122
Drug: Propranolol (Pr)
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (Pr) course treatment mean daily dose of 182 +/- 25 mg
Trial: 7914122
Drug: Proxodolol (Pd)
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxodolol (Pd) single dose of 0.04 g
Trial: 7914122
Drug: Propranolol (Pr)
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (Pr) single dose of 0.04 g
Trial: 7914122
Drug: Proxodolol (Pd)
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxodolol (Pd) and Propranolol (Pr) during course therapy
Trial: 3378465
Drug: Cefamandole (preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (preoperative and four postoperative doses)
Trial: 3378465
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no parenteral antibiotics)
Trial: 31112380
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (propofol, midazolam, or other sedatives)
Trial: 19200607
Drug: Gambling Symptom
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gambling Symptom Assessment Scale (G‐SAS)
Trial: 15287544
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide paste with anesthetic solution
Trial: 9596107
Drug: Regular inhaled
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular inhaled beta2-agonist (fenoterol) treatment
Trial: 3149455
Drug: Buserelin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin (200 micrograms subcutaneously daily or 400 micrograms intranasally three times daily)
Trial: 29338146
Drug: High liberal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High liberal group (15 mL/kg/hr intraoperatively and 10 mL/kg/hr six hours postoperatively)
Trial: 29338146
Drug: Low liberal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low liberal group (5 mL/kg/hr intraoperatively and six hours postoperatively)
Trial: 29338146
Drug: Restrictive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive group (1 mL/kg/hr intraoperatively and six hours postoperatively)
Trial: 23422913
Drug: BC-3781 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BC-3781 100 mg
Trial: 23422913
Drug: BC-3781 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BC-3781 150 mg
Trial: 17954698
Drug: Vancomycin 1
RxNorm normalized name: vancomycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 1 g every 12 h
Trial: 16970093
Drug: Yuquan Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yuquan Pill (YP) 6 g four times a day for 3 months
Trial: 16970093
Drug: Glucobay with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucobay with dietary and exercise therapy for 3 months (Control)
Trial: 9987507
Drug: Metoclopramide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 40 mg/day
Trial: 9987507
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg/day